

#### Glycosaminoglycans by LC-MS/MS

#### Frédéric Vaz, Ph.D. Clinical Biochemist IEM

Laboratory Genetic Metabolic Diseases (Lab GMD) Academic Medical Center Amsterdam, the Netherlands

# Glycosaminoglycans (GAGs)

- Glycosaminoglycans or *mucopolysaccharides* because of their viscous, lubricating properties, as found in mucous secretions
- Present on all animal cell surfaces in the extracellular matrix (ECM)
- Known to bind and regulate chemokines, cytokines, growth factors, morphogens, enzymes and adhesion molecules

### Glycosaminoglycan structure

 GAGs are long, unbranched, negatively charged heteropolysaccharide chains generally composed of a repeating disaccharide unit:



## **Glycosaminoglycans properties**

- At neutral pH, GAGs are highly negatively charged (carboxyl and sulfate groups)
- GAGs in aqueous solution are surrounded by a shell of water molecules → occupy an enormous hydrodynamic volume in solution
- Low compressability

#### Glycosaminoglycan types

- Heparin/Heparan sulfate
  - (N-acetlyl)glucosamineglycans
- Chrondroitin sulfate/Dermatan sulfate
  - (N-acetly)galactosaminoglycans
- Keratan sulfates
  - Galactose instead of uronic acid
- Hyaluronic acid
  - Non sulfated





#### Glycosaminoglycan structure



GAGs are linked to core proteins (except for hyaluronic acid) = proteoglycans or **mucopolysaccharides** 







## Glycosaminoglycans properties

- Heparin/Heparan sulfate (HSGAGs)
- Chrondroitin sulfate/Dermatan (CSGAGs)
  - O-linked glycans
- Keratan sulfate
  - N-linked or O-linked glycans

Synthesised in the golgi

- Hyaluronic acid
  - Direct secretion in extracelullar matrix from plasma membrane

# **Glycosaminoglycans functions**

- Many functions:
  - Heparin/Heparan sulfate (HS)
    - Histamine storage in mast cells (heparin)
    - Anticoagulant, LPL release (heparin)
    - Cell adhesion, regulation of cell growth
  - Chondroitin sulfate (CS)
    - Most abundant GAG in the body
    - Found in cartilage, tendon, ligament, aorta
  - Dermatan sulfate (DS)
    - Found in skin, blood vessels, heart valves
  - Keratan sulfate (KS)
    - tissue hydration, anti-adhesive
    - Found in cartilage and cornea
  - Hyaluronic acid
    - Major component of synovial tissues and fluid, vitreous body (eye)
    - Excellent lubricator and shock absorber

#### Mucopolysaccharidoses and mucolipidoses

Туре	Eponym	Enzyme deficiency	Storage product*
MPS I	Hurler,	α-L-iduronidase	DS, HS
	Hurler/Scheie,		
	Scheie		
MPS II	Hunter	Iduronate-2-sulfatase	DS, HS
MPS III A	Sanfilippo A	Heparan-N-sulfatase	HS
MPS III B	Sanfilippo B	N-acteyl-α-glucosaminidase	HS
MPS III C	Sanfilippo C	Acetyl-CoA:α-glucosaminide N-acetyltransferase	HS
MPS III D	Sanfilippo D	N-acetylglucosamine 6-sulfatase	HS
MPS IVA	Morquio A	Galactose-6-sulfatase	KS, CS
MPS IVB	Morquio B	β-galactosidase	KS
MPS VI	Maroteaux-Lamy	N-acetylgalactosamine-4-sulfatase	DS
MPS VII	Sly	β-glucuronidase	DS, HS, CS
MPS IX	2	Hyaluronidase	Hyaluronan
MLII	I-cell disease	N-acetylglucosaminyl-1-phosphotransferase	GAGs, sphingolipids
ML III	Pseudo-Hurler polydystrophy		an 20 - 856 Ar

\* DS: Dermatan sulfate, HS: Heparan sulfate, CS: Chondroitin sulfate, KS: Keratan sulfate, GAGs: glycosaminoglycans.

- Deficiency of lysosomal enzymes of GAGs degradation cause mucopolysaccharidoses and mucolipidoses
- Accumulation of GAGs in urine is a diagnostic marker

#### Mucopolysaccharidoses and mucolipidoses

- Main screening test is dimethylmethylene blue (DMB) test
- If elevated  $\rightarrow$  mucopolysaccharide electrophoresis
  - Reagent increasingly difficult to obtain
  - Not specific
  - Many false positives



- False negatives (MPS III and IV and mild patients)
- New assay needed
  - Methanolysis  $\rightarrow$  only HS and DS (not KS!)
  - Enzymatic digestion of GAGs to dissaccharides ightarrow analyse



#### Disaccharide nomenclature



- Abbreviated disaccharide nomenclature
- Easier than old (and long) system
- Cryptic at first but useful

N-Acetylgalactosamine (GalNAc)
 N-Acetylglucosamine (GlcNAc)

Glucuronic acid (GlcA)
 Iduronic acid (IdoA)

Lawrence, R et al, 2008. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. **PMID: 18376390** 

#### Disaccharide nomenclature



Lawrence, R et al, 2008. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. **PMID: 18376390** 

Non-reducing end descriptor
U = undesignated uronic acid
$D = \Delta^{4,0}$ -unsaturated uronic acid
G = glucuronic acid
I = Iduronic acid
g = galactose
Hexosamine descriptor
A = glucosamine
a = galactosamine
M = anhydromannose
T = anhydrotalose
Amine substitution
H = free amine
A = N-acetylated
S = N-sulfated
R = amino-tagged
Hexosamine O-sullation
0 = No sulfation
3 = 3-O-sulfation
4 = 4-O-sulfation
6 = 6-O-sulfation
9 = 3,6-O-disulfation
10 = 4,6-O-disultation
10 = 4,6-O-disultation
10 = 4,6-O-disultation
10 = 4,6-O-disultation Non-reducing end O-sulfation 0 = No sulfation 2 = 2-O-sulfation
10 = 4,6-O-disultation Non-reducing end O-sulfation 0 = No sulfation 2 = 2-O-sulfation 3 = 3-O-sulfation

#### Financial issue

• GAG degrading enzymes are REALLY expensive

– One incubation = ~100 euro!!

• Express your own!



	Nucleoticle Position				
Pperura	pei-ito	pEI-IIB	pEI-IIC	pet-tid	
T7 promoter with fac operation	13	1 43	1 (3	1 . 3	
risecona binding dia (KBS)	71.80	24.90	74 30	74 82	
Isdall pT-Fusion Next #FF-11d charing sim-	84-91	10-91	Ta-7'	06-91	
TZ gene 10 honoloted leader	82-121	09-121	59-121	011-120	
Banki I diovina Sta	*25-130	124-25	123-128	122-127	
TF territatis	79-245	193-244	197-243	196-342	
amoicílin researce (blai CRF	637 1014	0\$5 513	155 512	654 1511	
p86.822 origin of regionism	009-2832	1656-2581	1685-2933	1562.2329	
kaPmpeyn CRF	4212-5223	4211-3292.	4210-3287	4207-52EB	

#### Expression of GAG degrading enzymes

- All enzymes were expressed as His-tagged fusion proteins in E. coli
  - Keratanase II: Bacillus circulans
    Chondroitinase B: Pedobacter heparinus
    DS
  - Heparinase II: Flavobacterium heparinum HS
- Purify enzymes on HisLink Protein Purification Resin
- After dialysis, snap-freeze in liquid nitrogen and store at -80°C.



# Enzymatic hydrolysis of GAGs

- Enzymatic hydrolysis of GAGs to disaccharides:
  - 50  $\mu L$  urine diluted to 2 mM creatinine
  - Incubate with heparinase II, chondroitinase B and keritinase II for 2 h at 30°C
  - Add 15  $\mu L$  of 150 mM EDTA (pH7.0)
  - Add 125 ng of the internal standard, 4UA- 2S-GlcNCOEt-6S
  - Boil for 5 min to precipitate proteins, centrifuge
  - Apply supernatant to Amicon Ultra 10 kD centrifugal filter (Millipore) and centrifuge
  - Analyse filtrate by UPLC-MS/MS







## UPLC-MS/MS analysis

- Waters Quattro Premier XE (tandem) mass spectrometer with Acquity UPLC system
- Thermo Hypercarb HPLC column (100 × 2.1 mm, 5  $\mu$ m)
- Buffer A: 10 mM NH<sub>4</sub>HCO<sub>3</sub> (pH 10)
- Elute with buffer B: acetonitrile gradient of 0% to 20%
- Total run time 7 minutes



## Analysis of disaccharides

• Calibration curve of each disaccharide with 4UA-2S-GlcNCOEt-6S as internal standard



 Sum all disaccharides and report as total HS, DS and KS

- D0A0
- D0S0
- D0A6 and D2A0
- D2SO and D0S6
- D0a4
- D0a10
- g0A6
- g6A6
- D2S6

**HS** 

- **D0A0**
- DOSO
- DOA6 and D2A0
- D2S0 and D0S6
- D0a4
- D0a10
- g0A6
- g6A6
- D2S6

- **DOAO**
- DOSO
- DOA6 and D2A0
- D2SO and D0S6
- D0a4
- D0a10
- g0A6
- g6A6
- D2S6

<mark>HS</mark>

DS

- **DOAO**
- DOSO
- DOA6 and D2A0
- D2SO and D0S6
- D0a4
- D0a10
- g0A6
- <mark>g6A6</mark>



KS

**HS** 

• D2S6

- **D0A0**
- DOSO
- DOA6 and D2A0
- D2SO and D0S6
- <mark>D0a4</mark>
- <mark>D0a10</mark>
- g0A6
- <mark>g6A6</mark>

DS

KS

**HS** 

D2S6 HS and Heparin

If D2S6/D0A0 >0.8 exogenous heparin is possible



#### Practicalities

- Despite sample cleanup, after 20-30 urine samples peaks start shifting (less retention)
- Column needs to be reequilibrated by rinsing with buffer A
- Not a problem with plasma/CSF (under development)



# Reproducibility

	HS	DS	KS
Level 1	ng/ml	ng/ml	ng/ml
Average	833	175	1017
SD	98	19	111
vc %	11.8	10.9	10.9
Level 2	ng/ml	ng/ml	ng/ml
Average	1592	1263	2552
SD	160	153	236
vc %	10.0	12.1	9.3

- Control samples
- Two levels
- N=30

• Variation is quite high but differences between patients and controls are much larger

#### Total GAGs vs DMB test



#### **Clinical validation**



#### Performance

 Test is much better, especially for therapy monitoring
 One MPS | Scheie patient



## Conclusion

- Developed screening assay for mucopolysaccharidoses and mucolipidoses
- Better sensitivity and specificity than DMBtest + replaces GAGs electrophoresis
- Well suited as a first diagnostic test for all MPS subtypes

## Acknowledgements







# A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses

Eveline J. Langereis<sup>1</sup>, Tom Wagemans<sup>1,2</sup>, Wim Kulik<sup>2</sup>, Dirk J. Lefeber<sup>3</sup>, Henk van Lenthe<sup>2</sup>, Esmee Oussoren<sup>4</sup>, Ans T. van der Ploeg<sup>4</sup>, George J. Ruijter<sup>5</sup>, Ron A. Wevers<sup>3</sup>, Frits A. Wijburg<sup>1</sup>\*, Naomi van Vlies<sup>1,2</sup>







Heleen ten Brinke

PMID: 26406883

#### Questions?



#### Thank you for your attention!